TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods. 

TCT 2024 | Utilización de balones cubiertos de fármacos para el tratamiento de la rama lateral en técnica de stent provisional

Based on the CHOICE-CLOSURE and MASH studies, double ProGlide use was associated with fewer access complications than the Manta device. Consequently, the former became the most accepted therapeutic option.

The ACCESS-TAVI study included patients with severe aortic stenosis scheduled for transfemoral TAVI, randomly assigned (1:1) to suture-and-plug closure (ProGlide and Angio-Seal) or suture-only closure (double ProGlide).

The primary objective was assessing a composite of major or minor vascular access-related complications (VARC-3 criteria) during hospitalization. Ultrasound-guided puncture was recommended, while secondary access was used at the operator’s discretion.

A total of 454 patients were included. Their average age was 80 years; 51.7% of subjects were women, and 11.3% had peripheral arterial disease. Among patients, 49.6% had no calcification, 21.9% had mild calcification, and 97% showed mild or no tortuosity. Ultrasound-assisted puncture was used in 57.8% of cases, and the right transfemoral access was the preferred choice (88.7%). A secondary transradial access was used in 40.9% of cases.

Read also: TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions.

In the analysis of the primary endpoint, vascular complications, the suture/plug group had 27% events vs 54% in the suture-only group, with a relative risk [RR] of 0.55 (95% confidence interval [CI]: 0.44-0.68; P ≤0.001). Reduced events were mainly due to fewer minor vascular complications and bleeding grade ≥ 2.

The authors concluded that the use of suture-and-plug closure reduces vascular complications compared with suture-only closure and is associated with shorter time to hemostasis.

Presented by Tobias A. Rheude in the Late-Breaking Trials Sessions, TCT 2024, October 27-29, Washington, USA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Impact of Iliofemoral Disease on Post TAVR Clinical Outcomes: HOSTILE Score Validation

At present, transcatheter aortic valve replacement (TAVR) has been shown safe and effective for treating severe symptomatic aortic stenosis in high-surgical-risk patients. Moreover, its...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...